Figure S1: DC-shA20-FAP-OVA vaccine has potent antitumor activity. Mice were inoculated with B16-OVA (A) or EG7-OVA (B) followed by immunization with 1×10^6 DC-shA20-FAP (AF), DC-shA20-OVA (AO), DC-shA20-FAP-OVA (AF) or PBS on day 5 (n= 5 per group). Cotargeting FAP and OVA with AFO resulted in the greatest antitumor activity in both models (B16-OVA: AF vs AFO, p<0.05; AO vs AFO, p<0.05; EG7-OVA: AO vs AFO, p<0.05; AF vs AFO, p<0.05).